FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normal karyotype

Gilliland, 2002, The roles of FLT3 in hematopoiesis and leukemia, Blood, 100, 1532, 10.1182/blood-2002-02-0492 Meshinchi, 2001, Prevalence and prognostic significance of FLT3 internal tandem duplication in pediatric acute myelogenous leukemis, Blood, 97, 89, 10.1182/blood.V97.1.89 Kiyoi, 1999, Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia, Blood, 93, 3074 Rombouts, 2000, Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene, Leukemia, 14, 675, 10.1038/sj.leu.2401731 Abu-Duhier, 2000, FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group, Br. J. Haematol., 111, 190, 10.1046/j.1365-2141.2000.02317.x Kottaridis, 2001, Blood, 98, 1752, 10.1182/blood.V98.6.1752 Stirewalt, 2001, FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia, Blood, 97, 3589, 10.1182/blood.V97.11.3589 Whitman, 2001, Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study, Cancer Res., 61, 7233 Frohling, 2002, Prognostic significance of activating FLT3 mutations in younger adults (16–60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm, Blood, 100, 4372, 10.1182/blood-2002-05-1440 Yamamoto, 2001, Activating mutation of D835 within the activating loop of FLT3 in human hematologic malignancies, Blood, 97, 2434, 10.1182/blood.V97.8.2434 Boissel, 2000, Double induction in acute myelogenous leukemia (AML) with FLT3 gene internal tandem duplication [abstract], Blood, 96, 316 Estey, 2001, Comparison of idarubicin + ara-C-fludarabine + ara-C- and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts, Blood, 98, 3575, 10.1182/blood.V98.13.3575 Beran, 2001, High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens, Cancer, 92, 1999, 10.1002/1097-0142(20011015)92:8<1999::AID-CNCR1538>3.0.CO;2-B